» Articles » PMID: 24016071

CellMinerHCC: a Microarray-based Expression Database for Hepatocellular Carcinoma Cell Lines

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2013 Sep 11
PMID 24016071
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Therapeutic options for hepatocellular carcinoma (HCC) still remain limited. Development of gene targeted therapies is a promising option. A better understanding of the underlying molecular biology is gained in in vitro experiments. However, even with targeted manipulation of gene expression varying treatment responses were observed in diverse HCC cell lines. Therefore, information on gene expression profiles of various HCC cell lines may be crucial to experimental designs. To generate a publicly available database containing microarray expression profiles of diverse HCC cell lines.

Methods: Microarray data were analyzed using an individually scripted R program package. Data were stored in a PostgreSQL database with a PHP written web interface. Evaluation and comparison of individual cell line expression profiles are supported via public web interface.

Results: This database allows evaluation of gene expression profiles of 18 HCC cell lines and comparison of differential gene expression between multiple cell lines. Analysis of commonly regulated genes for signaling pathway enrichment and interactions demonstrates a liver tumor phenotype with enrichment of major cancer related KEGG signatures like 'cancer' and 'inflammatory response'. Further molecular associations of strong scientific interest, e.g. 'lipid metabolism', were also identified.

Conclusions: We have generated CellMinerHCC (http://www.medicalgenomics.org/cellminerhcc), a publicly available database containing gene expression data of 18 HCC cell lines. This database will aid in the design of in vitro experiments in HCC research, because the genetic specificities of various HCC cell lines will be considered.

Citing Articles

The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality?.

Krogh J Rev Endocr Metab Disord. 2024; 25(6):1077-1086.

PMID: 39388004 DOI: 10.1007/s11154-024-09916-7.


Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients.

El-Bendary M, Farid K, Arafa M, Elkashef W, Abdullah T, El-Mesery A J Egypt Natl Canc Inst. 2023; 35(1):26.

PMID: 37599312 DOI: 10.1186/s43046-023-00184-1.


Transcriptomic evidence for tumor-specific beneficial or adverse effects of TGFβ pathway inhibition on the prognosis of patients with liver cancer.

Desoteux M, Maillot B, Bevant K, Ferlier T, Leroux R, Angenard G FEBS Open Bio. 2023; 13(7):1278-1290.

PMID: 37195148 PMC: 10315808. DOI: 10.1002/2211-5463.13647.


Expression and Function of BMP and Activin Membrane-Bound Inhibitor (BAMBI) in Chronic Liver Diseases and Hepatocellular Carcinoma.

Weber F, Treeck O, Mester P, Buechler C Int J Mol Sci. 2023; 24(4).

PMID: 36834884 PMC: 9964332. DOI: 10.3390/ijms24043473.


The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer.

Nie H, Huang P, Jiang S, Yang Q, Hu L, Yang X Theranostics. 2021; 11(8):3898-3915.

PMID: 33664869 PMC: 7914341. DOI: 10.7150/thno.51712.


References
1.
Lee J, Chu I, Heo J, Calvisi D, Sun Z, Roskams T . Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40(3):667-76. DOI: 10.1002/hep.20375. View

2.
Schetter A, Heegaard N, Harris C . Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2009; 31(1):37-49. PMC: 2802675. DOI: 10.1093/carcin/bgp272. View

3.
Kupershmidt I, Su Q, Grewal A, Sundaresh S, Halperin I, Flynn J . Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One. 2010; 5(9). PMC: 2947508. DOI: 10.1371/journal.pone.0013066. View

4.
Castello G, Scala S, Palmieri G, Curley S, Izzo F . HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol. 2009; 134(3):237-50. DOI: 10.1016/j.clim.2009.10.007. View

5.
Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K . Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10(2):99-111. DOI: 10.1016/j.ccr.2006.06.016. View